Last reviewed · How we verify
metformin+ gliclazide
This combination reduces blood glucose by increasing insulin secretion and improving insulin sensitivity in type 2 diabetes patients.
This combination reduces blood glucose by increasing insulin secretion and improving insulin sensitivity in type 2 diabetes patients. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | metformin+ gliclazide |
|---|---|
| Also known as | rosiglitazone-metformin, Metformin |
| Sponsor | GlaxoSmithKline |
| Drug class | Antidiabetic combination (biguanide + sulfonylurea) |
| Target | Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity, while gliclazide stimulates pancreatic beta cells to increase insulin secretion. Together, they address both insulin resistance and beta-cell dysfunction in type 2 diabetes through complementary mechanisms.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)
- Headache
- Dizziness
- Lactic acidosis (rare)
Key clinical trials
- HbA1c Variability in Type II Diabetes (NA)
- Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial (NA)
- Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes (PHASE4)
- Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity (PHASE4)
- Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes
- Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metformin+ gliclazide CI brief — competitive landscape report
- metformin+ gliclazide updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI